DailyMed
Cure8 regulatory brief
Limited source text
What Cure8 can confirm
What We Know
Cure8 does not have enough reliable source text to summarize this article yet. Based on the article title and source metadata, this appears to be a regulatory update related to Tofacitinib, JAK inhibitor, and Medications. Use the original source link for the full details.
What Is Not Available
The source did not provide enough reliable article text for a source-grounded Cure8 brief. Study details, results, and limitations should be checked in the original source.
Source Details
Review the original publication for the complete reporting, methods, and context.
Regulatory update
Evidence type derived from source or registry metadata.
PublicationDailyMed
Study typeDrug Label Update
Indexed viaDailyMed
Source typeDrug label record
PublishedJun 26, 2026, 12:00 AM
Content availableMetadata only
Cure8 could not retrieve enough reliable source text to summarize this article. This page is based on the article title, source metadata, and Cure8 topic classification.
TOFACITINIB FDA label update (2026-07-06)
The FDA label update for tofacitinib lists ulcerative colitis among approved uses and highlights serious safety warnings that are directly relevant to people with IBD considering or taking this oral JAK inhibitor.
Successful treatment of refractory cutaneous Crohn's disease with upadacitinib: A case report.
Based on the title and source metadata, this appears to be a case report related to Crohn's disease, Upadacitinib, and JAK inhibitor. The original article is from JAAD case reports.
Early Response to Upadacitinib Predicts Long-Term Improvements in Crohn's Disease
Cure8 found this source from hmpgloballearningnetwork.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Upadacitinib. Open the original article for the...